Legato Biologics’s upstream process development capabilities are built upon state-of-the-art infrastructure and an experienced team dedicated to delivering high-quality biopharmaceutical products.
Legato Biologics offers comprehensive Cell Line Development (CLD) services, leveraging robust host cell lines such as CHO K1 and CHO K1 GS-KO to support diverse biopharmaceutical applications. Utilizing the proprietary DiTurbo™ dual-vector transfection system, Legato Biologics executes efficient gene expression and accelerated cell line establishment, ensuring high productivity and stability.
SparxNano™ technology is a cutting-edge platform designed to rapidly identify high-affinity, highly selective nanobodies targeting specified extracellular proteins within just four months.
uniQon™ technology delivers a nearly “true” site-specific conjugation solution, offering precise control over the drug-to-antibody ratio (DAR), resulting in optimal therapeutic performance.
Legato Biologics offers end-to-end Chemistry, Manufacturing, and Controls (CMC) services in America, specializing in monoclonal and multi-specific antibody development.
